Updated clinical information on multitargeted antifolates in lung cancer

Clinical Lung Cancer

Volumn 10, Issue SUPPL.1, 2009, Pages

  Scagliotti, Giorgio V ^a   Ceppi, Paolo ^a   Capelletto, Enrica ^a   Novello, Silvia ^a  

^a UNIVERSITY OF TURIN   (Italy)

Author keywords

Glycinamide ribonucleotide formyltransferase; Histology; Pemetrexed; Pharmacogenomics; Thymidylate synthase

Indexed keywords

5' METHYLTHIOADENOSINE PHOSPHORYLASE; 5'-METHYLTHIOADENOSINE PHOSPHORYLASE; DRUG DERIVATIVE; FOLIC ACID ANTAGONIST; GLUTAMIC ACID DERIVATIVE; GUANINE; MESSENGER RNA; PEMETREXED; PURINE NUCLEOSIDE PHOSPHORYLASE; THYMIDYLATE SYNTHASE;

CLINICAL TRIAL; DRUG ANTAGONISM; ENZYMOLOGY; GENE DELETION; GENETICS; HUMAN; LUNG NON SMALL CELL CANCER; LUNG SMALL CELL CANCER; LUNG TUMOR; METABOLISM; REVIEW;

CARCINOMA, NON-SMALL-CELL LUNG; CLINICAL TRIALS AS TOPIC; FOLIC ACID ANTAGONISTS; GENE DELETION; GLUTAMATES; GUANINE; HUMANS; LUNG NEOPLASMS; PURINE-NUCLEOSIDE PHOSPHORYLASE; RNA, MESSENGER; SMALL CELL LUNG CARCINOMA; THYMIDYLATE SYNTHASE;

EID: 67449091973     PISSN: 15257304     EISSN: 19380690     Source Type: Journal    
DOI: 10.3816/CLC.2009.s.006     Document Type: Article

References (44)

1. Calvert H. Folate status and the safety profile of antifolates. Semin Oncol 2002; 29(suppl 5):3-7. (Pubitemid 34564407)
2. Chu E, Mota AC, Fogarasi MC. Pharmacology of cancer chemotherapy: antimetabolites. In: Devita VT, Hellman S, Rosenberg SA, eds. Cancer: Principles and Practice of Oncology. 6th ed. Philadelphia: Lippincott Williams & Wilkins; 2001:388-415.
3. Hamada C, Tanaka F, Ohta M, et al. Meta-analysis of postoperative adjuvant chemotherapy with tegafur-uracil in non-small cell lung cancer. J Clin Oncol 2005; 23:4999-5006. (Pubitemid 46224006)
4. Saka H, Kitagawa C, Yamamoto M, et al. Phase I/II trial of TS-1 plus carboplatin in patients with advanced non-small cell lung cancer: final report of a Central Japan Lung Study Group trial-CJLSG0402. J Clin Oncol 2008; 26(15 suppl):710s (Abstract 19056).
5. Schultz RM, Patel VF, Worzalla JF, et al. Role of the thymidylate synthase in the antitumor activity of the multitargeted antifolate LY231514. Anticancer Res 1999; 19:437-43. (Pubitemid 29168274)
6. Goldman ID, Zhao ZR. Molecular, biochemical, and cellular pharmacology of pemetrexed. Semin Oncol 2002; 29(suppl 18):3-17. (Pubitemid 36176669)
7. Takimoto CH. New antifolates: pharmacology and clinical applications. Oncologist 1996; 1:68-81. (Pubitemid 126669374)
8. Chen VJ, Bewley JR, Andis SL, et al. Preclinical cellular pharmacology of LY231514 (MTA): a comparison with methotrexate, LY309887 and raltitrexed for their effects on intracellular folate and nucleoside triphosphate pools in CCRFCEM cells. Br J Cancer 1998; 78(suppl 3):27-34.
9. Hanna N, Shepherd FA, Fossella FV, et al. Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small cell lung cancer previously treated with chemotherapy. J Clin Oncol 2004; 22:1589-97. (Pubitemid 41079796)
10. Peterson P, Park K, Fossella F, et al. Is pemetrexed more effective in patients with non-squamous histology? A retrospective analysis of a phase III trial of pemetrexed versus docetaxel in previously treated patients with advanced non-small cell lung cancer (NSCLC). Eur J Cancer 2007; 5(suppl 4):363 (Abstract 6521).
11. Ohe Y, Ichinose Y, Nakagawa K, et al. Efficacy and safety of two doses of pemetrexed supplemented with folic acid and vitamin B12 in previously treated patients with non-small cell lung cancer. Clin Cancer Res 2008; 14:4206-12.
12. Scagliotti GV, Parikh P, von Pawel J, et al. Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer. J Clin Oncol 2008; 26:3543-51.
13. Ciuleanu TE, Brodowicz T, Belani CP, et al. Maintenance pemetrexed plus best supportive care (BSC) versus placebo plus BSC: a phase III study. J Clin Oncol 2008; 26(15 suppl):426s (Abstract 8011).
14. Patel JD, Hensing TA, Rademaker F, et al. Pemetrexed and carboplatin plus bevacizumab with maintenance pemetrexed and bevacizumab as first-line therapy for advanced non-squamous non-small cell lung cancer (NSCLC). J Clin Oncol 2008; 26(15 suppl):434s (Abstract 8044).
15. Seiwert TY, Connell PP, Mauer AM, et al. A phase I study of pemetrexed, carboplatin, and concurrent radiotherapy in patients with locally advanced or metastatic non-small cell lung or esophageal cancer. Clin Cancer Res 2007; 13:515-22. (Pubitemid 46225357)
16. Brade AM, Bezjak A, MacRae R, et al. A phase I study of concurrent pemetrexed/ cisplatin/radiation for unresectable stage IIIA/B non-small cell lung cancer. J Clin Oncol 2008; 26(15 suppl):409s (Abstract 7550).
17. Govindan R, Bogart J, Wang X, et al. A phase II study of pemetrexed, carboplatin and thoracic radiation with or without cetuximab in patients with locally advanced unresectable non-small cell lung cancer: CALGB 30407 - early evaluation of feasibility and toxicity. J Clin Oncol 2008; 26(suppl 15):401s (Abstract 7518).
18. Socinski MA, Weissman C, Hart LL, et al. Randomized phase II trial of pemetrexed combined with either cisplatin or carboplatin in untreated extensive-stage small-cell lung cancer. J Clin Oncol 2006; 24:4840-7. (Pubitemid 46630910)
19. Socinski MA, Smit EF, Lorigan P, et al. Phase III study of pemetrexed plus carboplatin (PC) versus etoposide plus carboplatin (EC) in chemonaive patients (pts) with extensive-stage disease small cell lung cancer (ED-SCLC): Interim results. Presented at: the 2008 Meeting of the American Society of Clinical Oncology; May 30-June 3; Chicago, Il. Available at: http://www.asco.org/ASCO/Abstracts.
20. Gronberg BH, Bremnes RM, Aasebo U, et al. A prospective phase II study: highdose pemetrexed as second-line chemotherapy in small-cell lung cancer. Lung Cancer 2008; 63:88-93.
21. Hanna NH, Ansari R, Bhatia S, et al. Pemetrexed in patients (pts) with relapsed small cell lung cancer (SCLC): a phase II study from the Hoosier Oncology Group. J Clin Oncol 2006; 24(18 suppl):378s (Abstract 7063).
22. Jett JR, Bernath AM, Foster R, et al. Phase II trial of pemetrexed and carboplatin in previously untreated extensive stage disease small cell lung cancer: a NCCTG study. J Clin Oncol 2008; 26(suppl 15):440s (Abstract 8066).
23. Hanauske AR, Eismann U, Oberschmidt O, et al. In vitro chemosensitivity of freshly explanted tumor cells to pemetrexed is correlated with target gene expression. Invest New Drugs 2007; 25:417-23. (Pubitemid 47222911)
24. Gomez HL, Santillana S, Vallejos C, et al. A phase II trial of pemetrexed in locally advanced breast cancer: clinical response and association with molecular target expression. Clin Cancer Res 2006; 12:832-8. (Pubitemid 43259865)
25. Giovannetti E, Mey V, Nannizzi S, et al. Cellular and pharmacogenetics foundation of synergistic interaction of pemetrexed and gemcitabine in human nonsmall-cell lung cancer cells. Mol Pharmacol 2005; 68:110-8. (Pubitemid 41002949)
26. Nishimura R, Nagao K, Miyayama H, et al. Thymidylate synthase levels as a therapeutic and prognostic predictor in breast cancer. Anticancer Res 1999; 19:5621-6. (Pubitemid 30093339)
27. Shirota Y, Stoehlmacher J, Brabender J, et al. ERCC1 and thymidylate synthase mRNA levels predict survival for colorectal cancer patients receiving combination oxaliplatin and fluorouracil chemotherapy. J Clin Oncol 2001; 19:4298-304. (Pubitemid 33096777)
28. Shiga H, Heath EI, Rasmussen AA, et al. Prognostic value of p53, glutathione S-transferase pi, and thymidylate synthase for neoadjuvant cisplatin-based chemotherapy in head and neck cancer. Clin Cancer Res 1999; 5:4097-104. (Pubitemid 30013791)
29. Takamura M, Nio Y, Yamasawa K, et al. Implication of thymidylate synthase in the outcome of patients with invasive ductal carcinoma of the pancreas and efficacy of adjuvant chemotherapy using 5-fluorouracil or its derivatives. Anticancer Drugs 2002; 13:75-85. (Pubitemid 34169530)
30. Shintani Y, Ohta M, Hirabayashi H, et al. Thymidylate synthase and dihydropyrimidine dehydrogenase mRNA levels in tumor tissues and the efficacy of 5-fluorouracil in patients with non-small-cell lung cancer. Lung Cancer 2004; 45:189-96. (Pubitemid 38891481)
31. Allegra CJ, Parr AL, Wold LE, et al. Investigation of the prognostic and predictive value of thymidylate synthase, p53, and Ki-67 in patients with locally advanced colon cancer. J Clin Oncol 2002; 20:1735-43. (Pubitemid 34273261)
32. Allegra CJ, Paik S, Colangelo LH, et al. Prognostic value of thymidylate synthase, Ki-67, and p53 in patients with Dukes' B and C colon cancer: a National Cancer Institute-National Surgical Adjuvant Breast and Bowel Project collaborative study. J Clin Oncol 2003; 21:241-50. (Pubitemid 46606152)
33. Merkelbach-Bruse S, Hans V, Mathiak M, et al. Associations between polymorphisms in the thymidylate synthase gene, the expression of thymidylate synthase mRNA and the microsatellite instability phenotype of colorectal cancer. Oncol Rep 2004; 11:839-43.
34. Ceppi P, Volante M, Saviozzi S, et al. Squamous cell carcinoma of the lung compared with other histotypes shows higher messenger RNA and protein levels for thymidylate synthase. Cancer 2006; 107:1589-96. (Pubitemid 44546920)
35. Huang C, Liu D, Nakano J, et al. E2F-1 over-expression associated with TS and surviving gene expressions in non-small-cell lung cancer. J Clin Oncol 2007; 25(suppl 18):426s (Abstract 7669).
36. Sowers R, Toguchida T, Qin J, et al. mRNA expression levels of E2F transcription factors correlate with dihydrofolate reductase, reduced folate carrier, and thymidylate synthase mRNA expression in osteosarcoma. Mol Cancer Ther 2003; 2:535-41.
37. Salon C, Merdzhanova G, Brambilla C, et al. E2F-1, Skp2 and cyclin E oncoproteins are upregulated and directly correlated in high-grade neuroendocrine lung tumors. Oncogene 2007; 26:6927-36. (Pubitemid 47609079)
38. Ceppi P, Volante M, Ferrero A, et al. Thymidylate synthase expression in gastroenteropancreatic and pulmonary neuroendocrine tumors. Clin Cancer Res 2008; 14:1059-64. (Pubitemid 351302551)
39. Zheng Z, Li X, Schell MJ, et al. Thymidylate synthase in situ protein expression and survival in stage I non-small-cell lung cancer. Cancer 2008; 112:2765-73. (Pubitemid 351969222)
40. Hashimoto H, Ozeki Y, Sato M, et al. Significance of thymidilate synthase gene expression level in patients with adenocarcinoma of the lung. Cancer 2006; 106:1595-601.
41. Nakagawa T, Tanaka F, Otake Y, et al. Prognostic value of thymidylate synthase expression in patients with p-stage I adenocarcinoma of the lung. Lung Cancer 2002; 35:165-70. (Pubitemid 34136094)
42. Higashiyama M, Kodama K, Yokouchi H, et al. Thymidylate synthase and dihydropyrimidine dehydrogenase activities in non-small cell lung cancer tissues: relationship with in vitro sensitivity to 5-fluorouracil. Lung Cancer 2001; 34:407-16. (Pubitemid 33041477)
43. Schmid M, Sen M, Rosenbach MD, et al. A methylthioadenosine phosphorylase (MTAP) fusion transcript identifies a new gene on chromosome 9p21 that is frequently deleted in cancer. Oncogene 2000; 19:5747-54.
44. Chattopadhyay S, Zhao R, Tsai E, et al. The effect of a novel transition state inhibitor of methylthioadenosine phosphorylase on pemetrexed activity. Mol Cancer Ther 2006; 5:2549-55. (Pubitemid 44650919)